Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
Tessa Therapeutics today announced the successful completion of dosing of the first patient cohort (n=3)…
Continue Reading
-
-
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Tessa Therapeutics today announced that the European Medicines Agency (EMA) has granted PRiority MEdicines (PRIME)…
Continue Reading -
Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer
Mr. McIntyre brings over 25 years of global financial, operational and legal experience, including over…
Continue Reading -
Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma
Tessa Therapeutics today announced the publication of results in the Journal of Clinical Oncology from…
Continue Reading -
Tessa Therapeutics Announces New Executive Leadership
Tessa Therapeutics today announced that Jeffrey H. Buchalter will assume the role of Chief Executive…
Continue Reading -
Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma
RMAT designation follows positive proof-of-concept data from two independent Phase I/II clinical studies conducted by…
Continue Reading -
Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020
State-of-the-art manufacturing facility will support clinical and commercial production of cell therapies for thousands of…
Continue Reading -
Tessa Therapeutics Establishes New Scientific Advisory Board
Tessa Therapeutics has established a new Scientific Advisory Board (SAB) with the appointment of a…
Continue Reading -
Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy
Tessa Therapeutics today announced ‘proof-of-concept’ data from the preclinical study of TT16, a first-of-its-kind combination…
Continue Reading -
Biopharma veteran, Jeffrey H. Buchalter is our newest independent board director
Mr Buchalter brings over thirty years’ experience in the biopharmaceutical industry, with strong corporate leadership…
Continue Reading